Table 1 Characteristics of participants at study screening and study entry, and antiretroviral regimens received during follow-up
Characteristic | Total (N = 278) | |
|---|---|---|
Age at entry (years) | Median (IQR) | 40 (34, 46) |
10th, 90th percentiles | 22, 55 | |
Sex | Male | 123 (44%) |
Female | 155 (56%) | |
Country | Brazil | 25 (9%) |
Haiti | 33 (12%) | |
India | 50 (18%) | |
Kenya | 32 (12%) | |
Malawi | 17 (6%) | |
Peru | 18 (6%) | |
South Africa | 56 (20%) | |
Thailand | 7 (3%) | |
Uganda | 34 (12%) | |
Zimbabwe | 6 (2%) | |
HIV-1 RNA at entry (copies/mL) | Median (IQR) | 20,444 (2,015, 91,371) |
10th, 90th percentiles | 272, 307,315 | |
CD4 count at entry (cells/mm³) | Median (IQR) | 169 (72, 288) |
10th, 90th percentiles | 23, 431 | |
HIV-1 Subtype | A1 | 49 (18%) |
B | 73 (26%) | |
C | 130 (47%) | |
D | 12 (4%) | |
CRF01_AE | 8 (3%) | |
Other | 6 (2%) | |
Duration of ART Prior to Entry (years) | Median (IQR) | 7.8 (5.5, 9.9) |
10th, 90th percentiles | 3.6, 11.8 | |
Duration of PI-based ART from last NNRTI use (years) | Median (IQR) | 3.2 (1.8, 5.0) |
10th, 90th percentiles | 1.3, 7.9 | |
NRTI resistance at screening | Resistance to any NRTI | 104 (37%) |
Susceptible | 174 (63%) | |
NNRTI resistance at screening | Resistance to any NNRTI | 146 (53%) |
Susceptible | 132 (47%) | |
PI resistance at screening | Resistance to any PI | 20 (7%) |
Susceptible | 258 (93%) | |
Randomized adherence support intervention | CPI + SOC | 128 (46%) |
SOC | 132 (47%) | |
Did not participate | 18 (6%) | |
NRTI components of regimen during follow-up | 3TC,ABC | 1 (< 1%) |
3TC,TDF | 6 (2%) | |
3TC,ZDV | 20 (7%) | |
FTC,TDF | 250 (90%) | |
FTC,TDF,ZDV | 1 (< 1%) | |
PI component(s) of regimen during follow-up | ATV | 1 (< 1%) |
RTV-boosted ATV | 103 (37%) | |
RTV-boosted LPV | 173 (62%) | |
SQV | 1 (< 1%) | |